The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer
CONCLUSIONS: The incorporation of a 5-day continuous intravenous infusion of rh-endostatin into platinum-based doublet chemotherapy has demonstrated both safety and efficacy in the treatment of advanced NSCLC. Furthermore, the baseline serum levels of CEA may potentially function as a predictor for the efficacy of rh-endostatin when combined with chemotherapy in NSCLC patients.CLINICALTRIALS: GOV: NCT05574998.PMID:38700579 | DOI:10.1007/s10637-024-01439-x (Source: Cancer Control)
Source: Cancer Control - May 3, 2024 Category: Cancer & Oncology Authors: Xinyi Liu Zihan Guo Lin Su Anli Zuo Min Gao Xiang Ji Jiameng Lu Shuran Yang Yunxiu Jiang Degan Lu Source Type: research
Tailoring micellar nanocarriers for pemetrexed in breast cancer: design, fabrication and in vitro evaluation
Nanomedicine, Ahead of Print. (Source: Future Medicine: Nanomedicine)
Source: Future Medicine: Nanomedicine - May 3, 2024 Category: Nanotechnology Authors: Nalla Usha Kumari Padakanti Sandeep Chary Ekta Pardhi Neelesh Kumar Mehra Source Type: research
Tailoring micellar nanocarriers for pemetrexed in breast cancer: design, fabrication and in vitro evaluation
Nanomedicine, Ahead of Print. (Source: Nanomedicine)
Source: Nanomedicine - May 3, 2024 Category: Nanotechnology Authors: Nalla Usha Kumari Padakanti Sandeep Chary Ekta Pardhi Neelesh Kumar Mehra Source Type: research
Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients
Curr Oncol. 2024 Apr 17;31(4):2274-2277. doi: 10.3390/curroncol31040168.ABSTRACTMaintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with Leishmania amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphoteric...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Sophie Laroumagne Julie Tronchetti Herv é Dutau Philippe Astoul Source Type: research
First-line avelumab plus chemotherapy in patients with advanced solid tumors: results from the phase 1b/2 JAVELIN Chemotherapy Medley study
Conclusions about clinical activity are limited by small patient numbers.CLINICALTRIALS: gov identifier, NCT03317496.PMID:38669053 | DOI:10.1158/2767-9764.CRC-23-0459 (Source: Cell Research)
Source: Cell Research - April 26, 2024 Category: Cytology Authors: Duncan A Wheatley Rossana Berardi Miguel A Climent Duran Anna Tomiak Alastair P Greystoke Anthony M Joshua Hendrik-Tobias Arkenau Lajos G éczi Javier Garcia-Corbacho Luis G Paz-Ares Syed A Hussain Lubos Petru želka Angelo Delmonte Colombe Chappey Joanna Source Type: research
Visceral Leishmaniasis Masquerading as Drug-Induced Pancytopenia in Lung Cancer Patients
Curr Oncol. 2024 Apr 17;31(4):2274-2277. doi: 10.3390/curroncol31040168.ABSTRACTMaintenance chemotherapy is a standard treatment in patients with non-progressive advance staged IV non-squamous non-small cell lung cancer after induction therapy. Here, we report the case of a 53-year-old man undergoing a maintenance monotherapy with pemetrexed who presented prolonged pancytopenia despite filgrastim injections. A bone marrow aspiration revealed a macrophage activation syndrome with Leishmania amastigotes. A Polymerase Chest Reaction testing confirmed the diagnosis of visceral leishmaniasis. Treatment with liposomal amphoteric...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Sophie Laroumagne Julie Tronchetti Herv é Dutau Philippe Astoul Source Type: research
Achieving complete metabolic response in stage IV lung adenocarcinoma with chemotherapy, nivolumab, ipilimumab, and salvage SBRT: A case report
A 55-year-old male with stage IV oncogene-negative, PDL1-negative lung adenocarcinoma demonstrated a complete metabolic response to a novel treatment strategy. This regimen combined double immune checkpoint inhibition (ICI) with chemotherapy, followed by stereotactic body radiotherapy (SBRT), after initial partial response to two cycles of carboplatin, pemetrexed, nivolumab, and ipilimumab, plus maintenance with nivolumab and ipilimumab. This case underscores the effectiveness of integrating multiple treatment modalities for non-small cell lung cancer (NSCLC). AbstractOncogene-negative, PDL1-negative metastatic non-small c...
Source: Respirology Case Reports - April 24, 2024 Category: Respiratory Medicine Authors: Salvador Gamez Casado,
Javier David Benitez Fuentes,
Beatriz Álvarez Rodríguez,
Gema García Ledo Tags: CASE REPORT Source Type: research
Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations
Cancers (Basel). 2024 Mar 22;16(7):1249. doi: 10.3390/cancers16071249.ABSTRACTContrary to Pemetrexed-containing chemo-immunotherapy studies, Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel (ABCP) treatment has consistently shown clinical benefit in prospective studies in patients with lung cancer and actionable mutations, where intracranial metastases are common. Here, we aimed to describe the real-life population of patients fit to receive ABCP after targeted therapy and quantify its clinical effect in patients with brain metastases. Patients treated in Cheshire and Merseyside between 2019 and 2022 were identified....
Source: Cancer Control - April 13, 2024 Category: Cancer & Oncology Authors: Marcus Rathbone Conor O'Hagan Helen Wong Adeel Khan Timothy Cook Sarah Rose Jonathan Heseltine Carles Escriu Source Type: research
101 Real-world analysis of the impact of pemetrexed in first-line maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
Real-world analyses of 1LM IO ± pemetrexed for NSQ a/ mNSCLC and how the COVID-19 pandemic reshaped treatment patterns and outcomes are lacking. This retrospective study characterised treatment patterns and their outcomes in this group of patients diagnosed in England prior to/during the COVID-19 pandemic. (Source: Lung Cancer)
Source: Lung Cancer - April 1, 2024 Category: Cancer & Oncology Authors: Fabio Gomes, Niall Gilding, Vivian Tan, Katerina Christoforou, Joanne Rule, Amine Aziez, Adam Januszewski, Anna Minchom Tags: NSCLC Systemic Treatment Source Type: research
